Safety Profile & Chemical Identity of Melanotan-2 Data from peer-reviewed publications and supplier datasheets Melanotan-2 Chemical Identity Synthetic cyclic heptapeptide analog of -MSH with lactam bridge Asp-Lys Melanotan-2 Documented Tolerance Profile Data from pilot clinical studies and peer-reviewed case reports Published clinical and preclinical data Four peer-reviewed trials and case reports Phase I pilot 1996, Wessells 1998-2000, case reports 2011-2014 2/3 Subjects with measurable pigmentation after 5 low doses of 0,01-0,03 mg/kg SC Doses studied (mg/kg SC) MC4R+ Central erectile function effects documented in double-blind crossover Evaluation method 20 years Cumulative review of Melanotan-I and Melanotan-II development since the University of Arizona Documented steps Case report Melanoma reported after Melanotan-2 injections + use of UV tanning beds Clinical context 3 generations Pharmacological evolution: MT2 (pan-MCR) bremelanotide (MC4R pref.) afamelanotide (MC1R selective) Receptor selectivity Important Notice Search Only Not intended for human consumption

Fight smarter
Xia, M., Yang, L., Sun, G., Qi, S
Hunger may return because the body adapts after weight loss, the medication dose changes, treatment is stopped, stress increases, sleep worsens, activity changes, or old eating patterns return
Moreover, MetS is also a good predictor for the development of T2D [6264]
Adrenocortical hormones not only destroy the plasticity and structure of neurons, but also exert cytotoxic effects by regulating neurotransmitters